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http://dx.doi.org/10.1016/j.ccr.2013.08.011SUMMARYMonosomy 7 and interstitial deletion of 7q (7/7q) are well-recognized nonrandom chromosomal abnor-
malities frequently found among patients with myelodysplastic syndromes (MDSs) and myeloid leukemias.
We previously identified candidate myeloid tumor suppressor genes (SAMD9, SAMD9-like = SAMD9L, and
Miki) in the 7q21.3 subband. We established SAMD9L-deficient mice and found that SAMD9L+/ mice as
well as SAMD9L/ mice develop myeloid diseases resembling human diseases associated with 7/7q.
SAMD9L-deficient hematopoietic stem cells showed enhanced colony formation potential and in vivo recon-
stitution ability. SAMD9L localizes in early endosomes. SAMD9L-deficient cells showed delays in homotypic
endosome fusion, resulting in persistence of ligand-bound cytokine receptors. These findings suggest that
haploinsufficiency of SAMD9L and/or SAMD9 gene(s) contributes to myeloid transformation.INTRODUCTION
The first report of monosomy 7 in patients with myeloid malig-
nancies was published in 1964, soon after the discovery of the
Philadelphia chromosome in 1960, that described the deletion
of a C group chromosome in three patients with refractory ane-
mia (myelodysplastic syndrome [MDS] by current criteria) that
subsequently developed acute myelogenous leukemia (AML)
(E.J. Freireich et al., 1964, Clin. Res., abstract). Since then,
7/7q has been established as the most representative chro-
mosomal abnormality in a wide variety of myeloid malignancies
(10%–20%), including sporadic MDS in the elderly as the soleSignificance
Chromosome loss may contribute to oncogenesis through m
which typically eliminate the function of one tumor suppressor
In this report, we investigate two related genes, SAMD9 and S
Taking advantage that mouse lacks SAMD9 gene, we estab
mice developmyeloid diseases strikingly resembling human di
of an adjacent geneMiki contributes to the development of MD
plify a mechanism for how large chromosome deletion can c
responsible genes.
Caanomaly, secondary AML in young patients, and AML carrying
leukemogenic chimeras as an additional chromosome abnor-
mality (Brunning et al., 2008; Johnson and Cotter, 1997).
Tremendous efforts have been made for decades to isolate the
responsible genes in 7q. Recent studies indicate that the most
frequent deletions among patients with MDS/AML occur within
two broad regions with ambiguous borders near bands 7q22
and 7q34 (Jerez et al., 2012).
We recently identified a common microdeletion cluster in
subband 7q21.3 in patients with juvenile myelomonocytic leu-
kemia using microarray comparative genomic hybridization
(mCGH) (Asou et al., 2009). This cluster contains three poorlyechanisms different from those caused by small deletions,
gene by the deletion of one allele and amutation in the other.
AMD9L, as candidate-responsible genes for monosomy 7.
lished SAMD9L-deficient mice and found that SAMD9L+/
seases associated with7/7q. Because haploinsufficiency
S through mitotic/nuclear abnormalities, our studies exem-
ontribute to oncogenesis via haploinsufficiency of multiple
ncer Cell 24, 305–317, September 9, 2013 ª2013 Elsevier Inc. 305
Figure 1. Development of Myeloid Dysplasia in SAMD9L-Deficient Mice
(A) Syntenic homology of the SAMD9L gene between humans and mice is presented. In humans, two related genes, SAMD9 and SAMD9L, exist in tandem,
whereas mice have only SAMD9L.
(B) Targeting strategy is illustrated. Part of the coding region of exon 2 is deleted and replaced by the b-galactosidase (b-gal) gene with the polyA (pA) and floxed
Neo-resistance genes for removal of the Neo-resistance cassette by Cre recombinase. The positions of the 50 probe for Southern blot and P1 and P2 primers for
genomic PCR are shown. Restriction sites are N (NcoI), RI (EcoRI), BII (BglII), A (ApaI), and K (KpnI).
(legend continued on next page)
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Myeloid Diseases Induced by SAMD9L Deficiencycharacterized genes: sterile a motif (SAM) domain-9 (SAMD9),
SAMD9L, andMiki (LOC253012). Althoughmutations have rarely
been seen in these genes, the genes reside proximal to the 7q22
band that is deleted in single copy in nearly 25% of patients with
AML andMDS (Asou et al., 2009). We also found thatMiki, a cen-
trosomal protein that promotes alignment of chromosomes at
metaphase, is a candidate gene responsible for mitotic/nuclear
abnormalities routinely observed in patients with MDS (Ozaki
et al., 2012).
The human SAMD9 (hSAMD9) and hSAMD9L genes share a
common gene structure and encode proteins with 60% amino
acid identity. A common ancestral gene of SAMD9/SAMD9L is
found in fish, frogs, and birds and shares roughly equal amino
acid identity with both genes. Most mammals including rats
have both SAMD9 and SAMD9L. However, mice have only
SAMD9L, and cows encode only an SAMD9 homolog (Li et al.,
2007), suggesting that SAMD9 and SAMD9L at least partially
complement each other’s functions. In humans, deleterious
mutations in the SAMD9 gene are known to cause normophos-
phatemic familial tumoral carcinosis (NFTC) (Topaz et al.,
2006), a rare autosomal recessive disease. Because NFTC is
characterized by abnormal inflammation of the skin and gingiva
that is induced by excessive signaling via tumor necrosis factor
a and/or interferon-g pathways, it has been suggested that
SAMD9 suppresses these inflammatory pathways (Chefetz
et al., 2008). In this study, we establish SAMD9L-deficient mice
to study possible roles of SAMD9L in the development of
myeloid malignancies and elucidate its biological function.
RESULTS
SAMD9L-Deficient Mice Developed Myeloid Disorders
Mouse synteny for human chromosome subband 7q21.3 ends at
the SAMD9L gene, and no SAMD9 gene is present in the mouse
genome (Figure 1A). We designed an SAMD9L knockout (KO)
vector in which the central portion of exon 2 (encoding the
entire SAMD9L protein) was removed and replaced with the
b-galactosidase cDNA and an SV40 polyA signal, followed by a
floxed neomycin-resistance cassette (Figure 1B). Recombinant
embryonic stem cell clones (Figure 1C) were used to create
SAMD9L+/ and SAMD9L/ mice.
SAMD9L mRNA was expressed ubiquitously in mice with the
highest expression in the kidney (Jiang et al., 2011). Quantitative
real-time PCR revealed that the level of SAMD9L mRNA expres-
sion in the kidney of SAMD9L+/ mice was 45% of that in WT(C) 50 Southern blot and 30 genomic PCR to detect homologous recombination are
panel), and the recombination-specific PCR product is indicated by the arrowhe
(D) SAMD9L transcripts analyzed by quantitative real-time PCR and normalized b
(top) or b-actin (bottom) antibody (right). SAMD9L genotypes are indicated belo
indicated between the two panels. Error bars, SD.
(E) Peripheral WBC count (left) or Hb level (right) is presented. Shaded areas indi
indicate SAMD9L/ mice; open circles represent SAMD9L+/ mice.
(F) Flow cytometric analysis of splenic cells is shown.
(G) Hematoxylin-eosin staining of formalin-fixed BM (panel 1), Giemsa-stained p
from SAMD9L-deficient mice that developed MDS is shown. Arrows indicate Ho
(H) Myeloid disease-free survival curves are illustrated. Data from mice that died
(I) Immunoblot analysis of mouse splenic cell extracts used SAMD9L (top) or b-
indicates the position of SAMD9L.
See also Table S1.
Camice, whereas the protein expression level decreased 4-fold
on immunoblots (Figure 1D).
SAMD9L/ (n = 15), SAMD9L+/ (n = 19), and SAMD9L+/+
(n = 28) littermates were observed regularly for signs of illness,
including routine examination of peripheral blood. Among 28
SAMD9L+/+ mice, all but 2 maintained consistent WBC counts
andhemoglobin (Hb) levels throughout the24-month observation
period (Figure 1E, shaded areas). Five of the SAMD9L+/+ mice
died during the observation period (Table S1 available online).
Among 34 SAMD9L+/ and SAMD9L/ mice, all but 1 (M-13)
showed normal WBC counts and Hb levels until the age of
12 months; thereafter, 12 mice (M-2, M-5, M-9, M-11, M-12,
M-14, M-16, M-17, M-19, M-20, M-21, and M-22) developed
neutropenia (WBC <4,000/ml), 3 mice (M-1, M-4, and M-7) suf-
fered from anemia (Hb <10 g/dl) with normal WBC counts,
whereas 3 mice (M-6, M-13, and M-23) showed an apparent
WBC increase (>15,000/ml) (Figure 1E). Of 23 mice associated
with those abnormal hematological findings, 18 had markedly
enlarged spleen (Table S1), in which Gr1/Mac1-positive myeloid
cells were proliferated (Figure 1F). All 15 mice developing cyto-
penia showed bone marrow (BM) with normal or even increased
cellularity (Figure 1G, panel 1), and myelodysplasia included
Pseudo-Pelger-Huet anomaly (panels 2 and 3), hypersegmented
neutrophils (panel 4), erythroblasts with abnormal nuclei (panels
5–7), Howell-Jolly body, polychromasia, anisopoikilocytosis
(panel 8), giant platelets (panel 9), and megakaryocytes with
round shape nuclei (panels 10 and 11). BM frequently showed
erythroid and/or myeloid maturation arrest (Figure 1G, panels
12 and 13). Based on Bethesda proposals for classification of
nonlymphoid hematopoietic neoplasms in mice (Kogan et al.,
2002), the types and frequencies of myeloid diseases included
myeloid dysplasia (8 of 15 SAMD9L/; 8 of 19 SAMD9L+/),
myeloid leukemia (1 of 15 SAMD9L/; 1 of 19 SAMD9L+/),
and myeloproliferative disease (1 of 19 SAMD9L+/).
SAMD9L-deficient mice died of myeloid disease (Figure 1H;
Table S1) at significantly higher frequency than SAMD9L+/+
mice (p < 0.05, log rank test). SAMD9L+/ mice that developed
myeloid diseases still expressed SAMD9L protein (Figure 1I),
and no mutations were detected in the coding regions of the
SAMD9L gene or mRNA.
MOL4070A Infection Accelerated Disease Latency
and Frequency
MOL4070A retrovirus (Wolff et al., 2003), a derivative of Molo-
ney murine leukemia virus, induces myeloid malignancies inshown. Germline (GL) and KO allele-derived bands are indicated by arrows (left
ad (right).
y HPRT (left) are shown. Immunoblot analysis of kidney extract used SAMD9L
w (left) or above (right). The relative expression ratio of SAMD9L to b-actin is
cate the range of values from 1 to +1 SD in SAMD9L+/+ mice. Closed circles
eripheral blood (panels 2–4, 8, and 9), and BM smears (panels 5–7 and 10–13)
well-Jolly bodies (panel 8). Scale bars, 5 mm.
of causes other than myeloid malignancies are censored.
actin (bottom) antibody. SAMD9L genotypes are indicated above. The arrow
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Figure 2. SAMD9L Deficiency Predisposes Mice to Myeloid Malignancies
(A) Myeloid disease-free survival curves of mice infected with MOL4070A retrovirus are presented. Data from mice that died of causes other than myeloid
malignancies are censored.
(B) Representative phenotypes of myeloid leukemia are shown. Wright-Giemsa staining of peripheral blood smears and results of flow cytometric analysis of
splenic cells are shown. Scale bars, 10 mm.
(C) Immunoblot analysis of extracts from splenic cells used SAMD9L (top) or b-actin (bottom) antibody. Mouse number and genotype are indicated above.
(D) Schematic illustration of the Evi1 (top) and Fbxl10 (bottom) genes identified as CISs is shown. Vertical arrows indicate viral integration sites.
(E) Southern blot analysis to detect retroviral integration is presented. Germline (GL) bands (arrows) and rearranged bands (arrowheads) are indicated.
(F) Evi1 (left) and Fbxl10 (right) transcripts analyzed by quantitative real-time PCR and normalized to the level of HPRT transcripts in splenic cells frommice with or
without integration of the indicated gene are shown. Horizontal short lines indicate median values.
(G) Survival curves of lethally irradiated mice that had been transfused with BM cells from SAMD9L/ or SAMD9L+/+ mice infected with either Evi1- or control
(GFP)-expressing retrovirus (left panel) or with either Fbxl10- or control (GFP)-expressing retrovirus (right panel) are illustrated.
See also Tables S2–S4.
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et al., 2004). When newborn mice were injected intraperitone-
ally with MOL4070A retrovirus, almost all SAMD9L+/ (12 of
14) and SAMD9L/ (10 of 12) mice died of nonlymphoid
hematopoietic neoplasms (Figure 2A; Table S2), much earlier
than mice that developed spontaneous myeloid malignancies
(Figure 1F). In contrast, MOL4070A-infected SAMD9L+/+ mice
developed myeloid diseases at a significantly lower frequency
(5 of 30; p < 0.01) within the 15-month observation period
(Figure 2A).308 Cancer Cell 24, 305–317, September 9, 2013 ª2013 Elsevier IncUnlike uninfected SAMD9L-deficient mice, which preferen-
tially developed MDS (13 of 30), 16 of 26 virus-infected mice
showed myeloid leukemias of various types such as immature
myeloid leukemia expressing myeloid (Gr1) and megakaryocyte
(CD61) markers (Figure 2B, M-4), myelomonocytic leukemia
with weak CD61 expression (M-20), and monocytic leuke-
mia partially positive for B cell (B220), erythroid (Ter119), or
megakaryocyte markers (M-26). Although leukemic cells from
two SAMD9L+/ mice showed no SAMD9L protein (Figure 2C,
M-15 and M-17) in immunoblots, long-distance PCR readily.
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mutation.
By the inverse PCRmethod (Yamashita et al., 2005), two com-
mon integration sites (CISs) were identified in leukemic samples
from SAMD9L-deficient mice (Table S3), whereas no CIS was
identified in samples from SAMD9L+/+ mice. In six samples
(M-9, M-17, M-19, M-20, M-24, and M-26), virus was found inte-
grated into the Evi1 gene (Figure 2D, upper) encoding a Zn finger
transcription factor, whereas three additional samples (14%;
M-4, M-18, and M-23) showed integration in the Fbxl10 (also
JHDM1B/Ndy1/KDM2B) gene (Frescas et al., 2007; Sa´nchez
et al., 2007) (Figure 2D, lower), which encodes a histone
H3K36 demethylase. Southern blot analysis showed polymor-
phic bands in all tumors (Figure 2E), indicating that the tumors
were composed largely of cells with these integration sites.
Quantitative real-time PCR analysis showed higher expression
levels than the median level of Evi1mRNA in nonintegrated sam-
ples (Figure 2F, left), whereas two (M-4 and M-18) maintained
higher Fbxl10 mRNA levels relative to nonintegrated samples
(Figure 2F, right panel).
Although Evi1 is well known to be overexpressed by retrovirus
insertion in mouse myeloid leukemia, the frequency of 6 (27.2%)
out of 22 myeloid malignancies carrying SAMD9L deficiency
was remarkably high compared with other leukemogenic factors
(usually around 5% or less) such as CBFb-MYH11 (Castilla et al.,
2004) and NUP98-HOXD13 (Slape et al., 2007). Enhancement of
leukemia incidence in SAMD9L-deficient mice combined with
Evi1 or Fbxl10 overexpression was further analyzed by retro-
virus-mediated in vitro gene transfer experiments (see Experi-
mental Procedures). Although no mice with transferred control
SAMD9L+/+GFP or SAMD9L/GFP BM cells (BMCs) developed
myeloid disorders during the 10-month observation period (Fig-
ure 2G), 3 of 11 mice with transferred SAMD9L+/+Evi1 cells died
of hematopoietic malignancies (Table S4). This relatively low fre-
quency of myeloid diseases induced by Evi1 gene transfer is in
agreement with previously published results by Buonamici et al.
(2004), Cuenco and Ren (2004), and Watanabe-Okochi et al.
(2008). In contrast, all mice (11 of 11) receiving transferred
SAMD9L/Evi1 cells died of hematopoietic malignancies,
particularly myeloid disorders (10 of 11; p < 0.01; Figure 2G,
left). Although not a statistically significant result (p = 0.082), we
also found that no mouse with transferred SAMD9L+/+Fbxl10
cells (n = 12) developed a hematopoietic malignancy, whereas
3 of 13 mice with transferred SAMD9L/Fbxl10 cells developed
myeloid malignancies (Figure 2G, right panel).
SAMD9L Deficiency Affects Hematopoietic Stem Cells
and Progenitors
Mouse (12 weeks old) BMCswere separated into three fractions:
long term (LT)-LSK (CD34, CD135(Flt3), lineage-negative
[Lin], Sca-1+, c-Kit+); short term (ST)-LSK (CD34+, CD135,
LSK); and multipotent progenitor (MPP; CD34+, CD135+ LSK).
Quantitative real-time PCR revealed that SAMD9L mRNA levels
in SAMD9L+/ or SAMD9L/ progenitors were roughly 50% or
0% of that in SAMD9L+/+ cells, respectively (Figure 3A). Reduc-
tion of SAMD9LmRNAwas supported by transcriptome analysis
of LSK cells using a next-generation sequencer (Figure 3B),
which also demonstrated that SAMD9L deficiency affects the
expression of only a few genes (Table S5). In addition, the totalCanumber and proportion of the three LSK fractions in BM from
SAMD9L-deficient mice were similar to those in BM from
SAMD9L+/+ mice (Figure 3C).
Despite these apparently small effects on the expression
profile and the repertoire of early hematopoietic progenitors, col-
ony-replating assay revealed prominent effects of SAMD9L defi-
ciency.BMCs (12weeksold)weregrown in semisolid culturewith
appropriate cytokines, and colonieswere counted and harvested
for replating after 2 weeks. Although cells from SAMD9L+/+ mice
formed fewer colonies by the third replating (Figure 3D), cells
from SAMD9L-deficient mice continued to form similar numbers
and sizes of well-differentiated colonies beyond the seventh
plating. The excess number of colonies formed was reduced by
retrovirus-mediated forced expression of Samd9L (Figure 3E).
These data suggested enhanced self-renewal and/or delays in
differentiation of SAMD9L-deficient stem cells.
Enhanced reconstitution ability of stem cells was demon-
strated by competitive repopulation assay using the Ly5 con-
genic mouse system. Irradiated Ly5.1 mice were transplanted
with LT-LSK cells from SAMD9L+/+ or SAMD9L-deficient Ly5.2
mice (10 weeks old) together with BMCs from SAMD9L+/+Ly5.1
mice. Increased WBC numbers of SAMD9L-deficient cells
relative to SAMD9L+/+ cells were observed in recipient mice
(Figure 3F). This was confirmed by limiting-dilution transplants
using three dose concentrations of BMCs, results of which
showed a higher frequency of multilineage repopulating cells
(myeloid and T/B lymphocytes) at 8 weeks in SAMD9L/ donor
BM (Figure S1), suggesting enhanced reconstitution ability of
stem cells and/or early hematopoietic progenitors.
In addition, growth advantage in the presence of cytokines was
evident in liquid cultures of c-Kit+ Lin (KL) cells (Figure 3G), which
wereamplifiedbyprimaryculturesofmouseBMCsusingstemcell
factor (SCF) and thrombopoietin (Kuribara et al., 2004). In this
system, the level of SAMD9L expression in SAMD9L+/ KL cells
was approximately 15% of that in SAMD9L+/+ cells (Figure 3H).
Hypersensitivity of SAMD9L-deficient progenitors to cyto-
kines was also shown in in vivo experiments (Figure 3I). Mice
were injected with cyclophosphamide (CPA) (day 0) and human
granulocyte colony-stimulating factor (hG-CSF) (days 1–4). WBC
counts of control SAMD9L+/+ mice without hG-CSF injection
decreased rapidly until day 2 or 3 and then the counts gradually
increased, whereas daily hG-CSF injection accelerated the
recovery, as previously demonstrated by others (Hattori et al.,
1990). SAMD9L-deficient mice showed significantly higher
WBC counts at the nadir (day 3).
Because mice developed MDS at an old age, we examined
the features of BM progenitors of old mice (26 months) by col-
ony-replating assay. Cells from SAMD9L+/+ non-MDS mice
formed fewer primary colonies (Figure 3J), up to one-third of
those from young mice (Figure 3D) probably due to aging, and
colony formation potential was lost within replating five times.
SAMD9L+/ non-MDS cells also formed fewer primary colonies;
however, like SAMD9L-deficient cells from young mice, the col-
ony formation potential was maintained during replating more
than five times. Interestingly, cells from SAMD9L+/ MDS mice
formed a reduced number of nonconcentric spread colonies,
which were apparently different from colonies formed by non-
MDS cells in shape (Figure 3K). These data suggested that
additional abnormalities transform BM progenitors to MDS cells.ncer Cell 24, 305–317, September 9, 2013 ª2013 Elsevier Inc. 309
Figure 3. Hypersensitivity to Cytokines of SAMD9L-Deficient Hematopoietic Progenitors
(A) SAMD9mRNA expression levels in hematopoietic cells are indicated below as a ratio relative to HPRTmRNAmeasured using quantitative real-time PCR. The
mean and SD in four independent experiments are shown. Error bars, SD.
(B) Comprehensive identification and characterization of the transcriptome of LSK cells from SAMD9L-deficient BM are presented. Scatterplots of log10(rpkm)
obtained for every transcript (>1 rpkm) in SAMD9L-deficient versus SAMD9L+/+ LSK cells are shown.
(C) The numbers of each fraction of LSK cells per 1,000 BMCs are presented. A representative result is shown. Similar results were obtained in three independent
experiments. Error bars, SD.
(D) The 23 104 BMCs obtained from 8-week-oldSAMD9L+/+, SAMD9L+/, and SAMD9L/mice were cultured inMethoCult M3434. Colonies were counted and
replated at 2 3 104 cells every 2 weeks. Error bars, SD.
(E) BMCs were infected with pMYs retrovirus indicated below, and 0.7 3 104 c-Kit+, GFP+ cells were sorted and cultured in MethoCult M3434. Colonies were
counted and replated at 2 3 104 cells every 10 days. iGFP, ires-GFP. Error bars, SD.
(F) Repopulation ability of SAMD9L+/+, SAMD9L+/, and SAMD9L/ LT-LSK cells isolated from 10-week-old mice is illustrated. The percentages of donor-
derived (Ly5.2+) SAMD9L+/ and SAMD9L/ cells in the total WBCs in the peripheral blood at periods indicated after transplantation are shown. Data are plotted
as means with error bars (SD). Representative results from three independent experiments are shown.
(G) BMCs were harvested and cultured in the presence of SCF and thrombopoietin (TPO) for 5 days. KL cells were then selected and cultured in SCF- and
TPO-containing medium. Cell numbers at the indicated period are shown. Error bars, SD.
(H) Immunoblot analysis of extracts from KL cells used SAMD9L (top) or b-actin (bottom) antibody. SAMD9L genotypes are indicated above.
(legend continued on next page)
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performed whole-exome sequencing on splenic cells from 17
mice that developed MDS or AML. We identified a total of 89
missense/nonsense/frameshift mutations that partially overlap-
ped with genes (or closely related genes) mutated in human
hematopoietic malignancies (Table S6).
SAMD9L Facilitates Homotypic Fusion of Endosomes
The above findings suggested that SAMD9L deficiency sensi-
tizes hematopoietic progenitors to cytokines. KL cells (purity
>90%) were harvested and starved of cytokines for 8 hr and
then cultured in SCF-containingmedium. InSAMD9L+/+ KL cells,
ERK was phosphorylated within 5 min of SCF stimulation (Fig-
ure 4A), followed by a rapid decline in phosphorylated-ERK
(pERK) level. In contrast, KL cells obtained from SAMD9L-defi-
cient mice maintained high levels of pERK even at 50 min after
the addition of SCF. These data suggested that SAMD9L is
involved in the turnover of cytokine receptors or negative feed-
back regulation for cytokine-derived signals.
A recent report demonstrated that hSAMD9L binds to an
endosome protein, Rgl2 (Hershkovitz et al., 2011), which regu-
lates cytokine receptor-derived signals (Takaya et al., 2007).
Indeed, immunostaining using SAMD9L antibody showed a
vesicular pattern of SAMD9L localization in approximately 15%
of KL cells (Figure 4B, panel 1) or lung fibroblasts (panel 4) that
overlapped with the localization of Rab5, an early endosomal
protein (Bucci et al., 1992).
Ligand-bound cytokine/growth factor receptors are endocy-
tosed and transitioned to endosomes and then degraded in lyso-
somes (Haas et al., 2005; Karlsson et al., 2006; Luzio et al., 2009).
To analyze this process, we used lung fibroblasts expressing
endogenous platelet-derived growth factor receptor (PDGFRb)
because sufficient numbers of cells can be obtained for pulse-
chase experiments, and these cells have a large cytoplasmic
volume allowing detailed observation of endosomes.
In pulse-chase studies, cell surface receptors were labeled
with biotin, enabling us to discriminate cell surface and endocy-
tosed receptors (Karlsson et al., 2006; Roberts et al., 2001) (see
Experimental Procedures). Cell surface PDGFRb was internal-
ized within 5 min after PDGF stimulation of SAMD9+/+ fibroblasts
(Figure 4C, lanes 1–4), followed by an increase in endocytosed
receptor levels after 15 min (lane 3), which then returned to low
levels within 30 min (lane 4).
When we repeated this experiment using lung fibroblasts with
reduced expression of SAMD9L by small hairpin RNA (sh#4
fibroblasts) (Figure 4D, lane 2), surface receptor levels in sh#4
fibroblasts behaved in a similar manner (Figure 4C, upper panel,
lanes 5–8); however, these cells showed a 5-fold higher accu-
mulation of endocytosed receptors relative to WT fibroblasts
(lower panel, lanes 7 and 8). We established cells that coex-
pressed a FLAG-tagged sh#4-resistant SAMD9L (Figure 4D,
lane 3) and found that endocytosed PDGFRb accumulation
was reduced to levels found in SAMD9L+/+ fibroblasts (Figure 4C,(I) Mice (four each) were injected with CPA on day 0 and hG-CSF daily from day
(J) The 23 104 BMCs obtained from 26-month-old SAMD9L+/+ non-MDS, SAMD9
Colonies were counted and replated at 2 3 104 cells every 10 days. Error bars, S
(K) Representative images show colonies obtained from 26-month-old mice. Sca
See also Tables S5 and S6 and Figure S1.
Calower panel, lanes 11 and 12), excluding the possibility of off-
target effects.
We established lung fibroblasts from SAMD9L+/ and
SAMD9L/ mice, which expressed SAMD9L protein at levels
of approximately 25% or 0%, respectively, of that in SAMD9L+/+
mice (Figure 4E, top panel). Both SAMD9L+/ and SAMD9L/
cells showed endocytosed receptor accumulation (Figure 4E,
middle) and persistent phosphorylation of Akt (Figure 4E, bottom
two panels) like sh#4 fibroblasts.
To elucidate the roles of SAMD9L in the metabolism of endo-
cytosed PDGFRb, we observed endosomes and lysosomes in
lung fibroblasts expressing a myc-tagged PDGFRb. In PDGF-
starved fibroblasts, myc-PDGFRb localized to the cell surface
as well as to the cytoplasm with a diffuse and vesicular pattern
(Figure 4F, panel 1), whereas an early endosome marker EEA1
localized to the cytoplasm (panel 5). PDGF stimulation for
5 min induced little change (Figure 4F, panels 2 and 6). However,
upon PDGF treatment for 15 min, myc-PDGFRb on the cell sur-
face was barely visible, and relatively large vesicles (>1 mm) con-
taining myc-PDGFRb or EEA1 were observed in the perinuclear
region (Figure 4F, panels 3, 30, 7, and 70; Figure 4G). Some
regions (approximately 30%) within the large vesicles were pos-
itive for both EEA1 and PDGFR on immunostaining analyses
(Figure 4F, panel 110). Thirty minutes after the addition of
PDGF, vesicle size decreased (Figure 4F, panels 4 and 8), and
only a few vesicles were positive for both EEA1 and PDGFRb
(Figure 4F, panel 12). Instead of EEA1, lysosome-associated
membrane protein 1 (Lamp1)-positive vesicles were fused to
approximately 30% of those containing PDGFRb (Figure 4H,
panel 3). This time course is in agreement with a previous report
by Karlsson et al. (2006), showing that early endosomes contain-
ing growth factor receptors increase in size via homotypic fusion
and then transition to late endosomes that fuse with lysosomes.
We repeated this experiment using sh#4 fibroblasts. Although
little difference was observed by PDGF stimulation for 5 min
(Figure 4F, panel 14), after 15 min of PDGF treatment,
PDGFRb-containing vesicles moved to the perinuclear region,
but these vesicles were noticeably smaller (Figure 4F, panels
15 and 150; Figure 4G). Shrunken myc-PDGFR-containing vesi-
cles in the perinuclear region were also observed in SAMD9L+/
and SAMD9L/ fibroblasts 15 min after PDGF stimulation (Fig-
ure 4G). Thirty minutes after the addition of PDGF, few endo-
somes in sh#4 fibroblasts were positive for both Lamp1 and
PDGFRb (Figure 4H, panel 6), suggesting that SAMD9L pro-
motes the fusion of early endosomes that will transition to late
endosomes and/or lysosomes.
It was reported that EEA1 promotes homotypic fusion of endo-
somes (Christoforidis et al., 1999; Mills et al., 1998), and EEA1
downregulation delays the degradation of epidermal growth fac-
tor receptor (Leonard et al., 2008). Indeed, when EEA1 expres-
sionwas downregulated using EEA1-specific siRNAs (Figure 5A),
accumulation of endocytosed PDGFRb and persistent phos-
phorylation of Akt were also evident 15 or 30min after stimulation1 to day 4. Average WBC counts and SD are shown.
L+/ non-MDS, and SAMD9L+/MDSmice were cultured inMethoCult M3434.
D.
le bars, 100 mm.
ncer Cell 24, 305–317, September 9, 2013 ª2013 Elsevier Inc. 311
Figure 4. Involvement of SAMD9L in Homotypic Fusion of Endosomes
(A) KL cells fromSAMD9L+/+, SAMD9L+/, and SAMD9L/mice were SCF starved for 8 hr and then stimulated with SCF for the indicated number of minutes. The
results of immunoblot detection of pERK and total ERK are shown.
(B) A KL cell (panels 1–3) or lung fibroblast (panels 4–6) was stained with SAMD9L and Rab5 antibodies. Scale bars, 5 mm.
(C) Immunoblot detection of cell surface and endosomal PDGFRb that were biotinylated and precipitated separately is shown.
(D) Immunoblot analyses used SAMD9L (top), FLAG (middle), or b-actin (bottom) antibody to detect proteins in parent SAMD9L+/+ lung fibroblasts (lane 1), cells in
whichSAMD9Lexpressionwasconstitutivelydownregulatedbysh#4 (lane2), andcells simultaneously expressingsh#4andFLAG-SAMD9L (sh#4 resistant) (lane3).
(E) Immunoblot detection used the antibodies indicated on the left. Cell extracts from SAMD9L+/+, SAMD9L+/, or SAMD9L/ lung fibroblasts were subjected to
immunoblot analysis except for the middle panel, in which biotinylated and precipitated endosomal PDGFRb was used.
(legend continued on next page)
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Figure 5. Involvement of SAMD9L in the
Metabolism of Cytokine Receptor
(A) Immunoblot analyses used EEA1 (top) or
b-actin (bottom) antibody to detect proteins
in lung fibroblasts treated with EEA1 shRNA#4
(lane 1) or shRNA#8 (lane 2), and in parental
cells (lane 3).
(B) Immunoblot detection used the antibodies
indicated on the left. Cell extracts from lung
fibroblasts expressing shRNA#4 (lanes 1–4)
and shRNA#8 (lanes 5–8) were subjected to
immunoblot analysis except for the middle
panel, in which biotinylated and precipitated
endosomal PDGFRb was used.
(C) 293 cells were transiently transfected with
either empty p33FLAG-CMV10 or p33FLAG-
CMV10-SAMD9L vector. Whole-cell extracts
(lanes 1 and 2) or immunoprecipitated products
(IP) using control IgG, FLAG, or EEA1 antibody
were subjected to immunoblot analysis (IB) using
antibodies indicated on the left.
(D) IP of 32D cells using antibodies in (C) were
subjected to IB using antibodies indicated on
the left.
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Myeloid Diseases Induced by SAMD9L Deficiencywith PDGF (Figure 5B, upper- and lower-middle panels, lanes 3,
4, 7, and 8). By coimmunoprecipitation analyses, we obtained
data showing that SAMD9L binds to EEA1 in 293 cells (Figure 5C,
lanes 5 and 6) or 32D myeloid cells (Figure 5D), suggesting that
SAMD9L and EEA1 are crucial components of a protein complex
that facilitate the degradation of cytokine receptors through the
homotypic fusion of endosomes.
Application of the Results in Mice to Human Myeloid
Malignancies with –7/7q–
In human, the related SAMD9 (hSAMD9) gene in addition to
SAMD9L (hSAMD9L) was expressed in hematopoietic progeni-
tors (Figure 6A). The unusual gene distribution among mammals
(see Introduction) suggests that SAMD9 and SAMD9L at least
partially complement each other’s functions. We introduced
FLAG-tagged hSAMD9 or hSAMD9L transgenes into lung fibro-
blasts established from SAMD9L/ mice (Figure 6B). Relative
to SAMD9L/ cells infected with empty virus (Figure 6C, lanes
7 and 8), those expressing hSAMD9 or hSAMD9L showed a 10-
or 3-fold decrease in endosomal PDGFRb (Figure 6C, lanes 11
and 12, and 15 and 16), respectively, suggesting that hSAMD9
or hSAMD9Lalso downregulates cytokine signalings. In addition,
coimmunoprecipitation analyses revealed that both hSAMD9
and hSAMD9L interact with EEA1 (Figure 6D, lanes 4, 6, and 10).
To test whether SAMD9L plays roles in cytokine-emanating
signal transduction in human leukemia cells harboring mono-
somy 7, F-36P cells (Chiba et al., 1991) were infected with virus(F) Lung fibroblasts expressingmyc-PDGFRb (panels 1–12) and those expressing
followed by stimulation with 100 ng/ml PDGF-BB for the indicated lengths of time
150, 190, and 230 show 5-fold enlargements of endosome-rich regions. Scale bar
(G) Longitudinal diameter of PDGFR-positive endosomes was measured using Im
(H) Cells stimulated with 100 ng/ml PDGF-BB for 30 min were stained with Myc
Nuclei were stained with Hoechst 33342 in (B), (F), and (H).
Cacontaining SAMD9L cDNA (Figure 6E, left panel). In cells infected
with empty virus, substantial levels of ERK phosphorylation
continued to be observed more than 1 hr after GM-CSF stimula-
tion (Figure 6E, middle panels). However, ERK phosphorylation
decreased to less than 10% within 30 min in cells expressing
SAMD9L (Figure 6E, right).
We determined the copy number of SAMD9 and SAMD9L
genes in 60 unselected MDS and AML samples using mCGH
and qPCR (Asou et al., 2009). A total of 17 patients (17 of 60,
28%) carried one copy each of the SAMD9 and SAMD9L genes.
The remaining 43 patients had two or more copies of both
SAMD9 and SAMD9L genes, and no patient harbored missense
or nonsensemutations. Quantitative real-time PCR revealed that
SAMD9 or SAMD9L mRNA expression levels in BM mononu-
clear cells in patients with MDS/AML with one gene copy were
significantly reduced relative to those carrying two or more
copies (p < 0.01; Figure 6F). Intriguingly, the mRNA expression
level of SAMD9 correlated with that of SAMD9L in MDS/AML
cells (Figure 6G), suggesting that loss of one 7q allele results in
simultaneous reductions in SAMD9 and SAMD9L expression.
To test whether Evi1 or Fbxl10 overexpression contributes to
human leukemogenesis associated with 7/7q, as they did in
SAMD9L-deficient mice (Figure 2F), we measured Evi1 and
Fbxl10 mRNA levels in patients with MDS/AML. Evi1 expres-
sion levels were higher (>0.5 of HPRT expression levels) in
5 of 17 (29%) and 3 of 43 (7.0%) samples carrying haploid
or diploid/polyploid for SAMD9/SAMD9L genes, respectivelyreduced levels of SAMD9L (sh#4; panels 13–24) were starved of PDGF for 16 hr,
. Cells were stained with the antibodies indicated on the left. Panels 30, 70, 110,
s, 10 mm.
ageJ software (mean and SD of 200 endosomes).
and Lamp1 antibodies. Scale bars, 5 mm.
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Figure 6. Function and Expression of hSAMD9 and hSAMD9L
(A) SAMD9 (top) and SAMD9L (bottom)mRNA expression levels in hematopoietic cells are indicated on the left as a ratio relative to b-actin mRNAmeasured using
quantitative real-time PCR. The mean and SEM in four independent experiments are shown.
(B) Immunoblot analysis used FLAG (upper) or b-actin (bottom) antibody. Lung fibroblasts from SAMD9L/ mice (lane 1), cells infected with the empty pMXs
(lane 2), pMXs-FLAG-hSAMD9 (lane 3), or pMXs-FLAG-hSAMD9L (lane 4) virus are shown.
(C) Lung fibroblasts from SAMD9L+/+ mice infected with the empty pMXs virus (lanes 1–4), fibroblasts fromSAMD9L/mice infected with the empty pMXs (lanes
5–8), pMXs-FLAG-hSAMD9 (lanes 9–12), and pMXs-FLAG-hSAMD9L (lanes 13–16) virus are presented. Cells were starved of PDGF for 16 hr and then stimulated
with PDGF-BB (100 ng/ml) for the periods indicated above. Immunoblot detection of endosomal PDGFRb is shown.
(D) 293 cells were transiently transfected with either empty p33FLAG-CMV10 or p33FLAG-CMV10-SAMD9L vector. Whole-cell extracts (lanes 1 and 2) or
immunoprecipitated products using control IgG, FLAG, or EEA1 antibody were subjected to immunoblot analysis using EEA1 (top), FLAG (middle), or hSAMD9L
(bottom) antibody.
(E) F-36P cells were infected with empty retrovirus or virus containing mouse SAMD9L cDNA and cytokine starved for 12 hr and then stimulated with
SCF for the indicated number of minutes. The results of immunoblot detection of pERK and total ERK (left and middle), and myc and b-actin (right)
are shown.
(legend continued on next page)
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ous reports by Barjesteh van Waalwijk van Doorn-Khosrovani
et al. (2003) and Lugthart et al. (2008). In contrast, there was no
significant difference in Fbxl10 mRNA expression levels (Fig-
ure 6H, right).
DISCUSSION
In this paper, we demonstrated that SAMD9L haploinsufficiency
ultimately induces the development of myeloid diseases in mice.
Because humans have the related SAMD9 gene that encodes a
protein that compensates for the function of SAMD9L at least in
part, loss of one copy of each of the SAMD9 and SAMD9L genes
(i.e.,SAMD9+/SAMD9L+/) as a result of7/7qmay not corre-
spond to SAMD9L+/ in mice. However, simultaneous reduction
of SAMD9 andSAMD9LmRNAby loss of 7q (Figure 6F) suggests
that SAMD9/SAMD9L function in human cells harboring7/7q
is parallel to SAMD9L function in SAMD9L+/ mouse cells.
SAMD9L haploinsufficiency in the natural course induced
the development of MDS in elderly mice (Figure 1F), mimicking
the typical clinical association between monosomy 7 as a sole
anomaly and sporadic MDS in elderly humans (Jaffe et al.,
2001). Enhancement of stem cell self-renewal and/or delay in dif-
ferentiation of early progenitors was observed in both young and
old SAMD9L+/ non-MDS mice (Figures 3D and 3J); however,
BMCs from old SAMD9L+/ MDS mice lost these features. This
suggests that additional genetic and/or epigenetic alterations
(other than age-related ones) that suppress stem cell self-
renewal and/or induce differentiation of early progenitors play
critical roles in the development of MDS. We consider that
SAMD9L haploinsufficiency contributes to MDS by protecting
stem cell(s) harboring such MDS-causative genetic and/or
epigenetic alterations from depletion.
In addition to sporadic MDS in elderly individuals, 7/7q
frequently occurs in younger patients during the advancement
of secondary AML/MDS in radiation-induced and therapy-
related cases (Pedersen-Bjergaard et al., 2008), as well as during
the development of AML/MDS among patients with a propensity
for myeloid diseases such as patients with Fanconi anemia and
congenital neutropenia. 7/7q is also often detected as an
additional chromosome abnormality in patients with AML
harboring a variety of leukemogenic chromosome translocations
and well-known gene abnormalities including Evi1 overexpres-
sion (Barjesteh van Waalwijk van Doorn-Khosrovani et al.,
2003; Jaffe et al., 2001; Lugthart et al., 2008). The role of
7/7q that promotes leukemogenesis caused by such a wide
variety of genetic alterations to different subtypes ofmyeloidma-
lignancies appears to correspond to the potential of SAMD9L
haploinsufficiency that promotes diverse pathways activated
by retrovirus insertion toward different types of myeloid leukemia
in younger mice (Figures 2A and 2B; Table S2).
SAMD9L haploinsufficiency sensitized hematopoietic progen-
itors to cytokines both in vitro and in vivo (Figures 3G and 3I). This(F) Ratios of SAMD9 and SAMD9L mRNAs relative to HPRT mRNA in the BM
diploid/polyploid (right) are shown. Horizontal lines indicate the median.
(G) Correlation between the relative expression levels of SAMD9 (horizontal) a
presented. Regression lines and correlation coefficient (r) are indicated.
(H) Relative expression levels of Evi1 (left) and Fbxl10 (right) mRNA to HPRT mR
Cais consistent with a previous report indicating that G-CSF prefer-
entially stimulates proliferation of monosomy 7 progenitors
carrying nonmutated G-CSF receptor (Sloand et al., 2006). In
addition, a correlation has been reported between the develop-
ment of myeloid malignancies harboring monosomy 7 and LT
treatment of aplastic anemia and congenital neutropenia with
G-CSF (Kojima et al., 2002; Weinblatt et al., 1995), supporting
that the loss of SAMD9/SAMD9L genes plays crucial roles in
the growth advantage under the presence of cytokines and
leukemogenic process of progenitors harboring 7/7q.
The presence of broad and divergent deletion regions in
patients with 7q AML/MDS suggests that the total loss of one
tumor suppressor gene (which usually occurs by the deletion
of one allele and a mutation in the other) is unlikely to be respon-
sible for myeloid transformation by 7/7q (Jerez et al., 2012).
Rather, like current models proposed for 5q (another large
deletion frequently found inMDS; Brunning et al., 2008), haploin-
sufficiencies of multiple genes play critical roles in the promotion
of myeloid diseases (Ebert, 2009). The 5q region encodes mul-
tiple (candidate) causative proteins that carry out a broad spec-
trum of biochemical functions. Haploinsufficiency of each gene
is likely responsible for the corresponding clinical symp-
toms, such as anemia, thrombocytosis, clonal dominance, and
response to lenalidomide (a key drug for treating 5q MDS).
We consider that SAMD9/SAMD9L and Miki, the latter of
which we recently reported as being involved in the abnormal
morphology characteristic of MDS (Ozaki et al., 2012), are mem-
bers of multiple causative genes on 7q, whose haploinsuffi-
ciency in combination plays crucial roles in the development of
myeloid malignancies. Because SAMD9 and SAMD9L compen-
sate each other’s function at least in part, heterozygous loss of
both SAMD9 and SAMD9L genes may be required to develop
human myeloid diseases, and that is why mutations have not
been identified in either gene. Careful analysis of small deletions
and mutations using high-throughput sequencing may help to
identify other key genes in this region that contribute to myeloid
transformation by loss of one 7q allele.
EXPERIMENTAL PROCEDURES
Mouse Experiments
SAMD9L-deficient mice were established according to standard procedures
described in Supplemental Experimental Procedures. Evi1 gene transduction
was performed according to the method described previously by Jin et al.
(2007). Fbxl10 transduction was performed using the method described in
Supplemental Experimental Procedures. Newborn mice were inoculated intra-
peritoneally with 100 ml MOL4070A retrovirus solution containing approxi-
mately 1 3 105 infectious particles. Retroviral integration sites were identified
using iPCR as described previously by Yamashita et al. (2005). Peripheral
blood chimerisms of the recipient mice were analyzed as previously described
(Nagamachi et al., 2010). To analyze the effect of hG-CSF, mice (9 weeks of
age) that had been intraperitoneally injected with CPA (Shionogi Pharmaceu-
ticals, Osaka) at a dose of 100 mg/kg on day 0, were given 0.1 mg of human
G-CSF (Miltenyi Biotec, Bergisch Gladbach) per mouse per day, or control
vehicle for 4 days from day 1 to day 4. Blood samples for the measurement-MNC of patients with MDS/AML that are SAMD9/SAMD9L haploid (left) or
nd SAMD9L (vertical) mRNA to HPRT mRNA from MNCs described in (F) is
NA in MNCs of patients with MDS/AML described in (F) are shown.
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Myeloid Diseases Induced by SAMD9L Deficiencyof WBC count were obtained 5 hr after each injection and 30 hr after the injec-
tion on day 4. All mice were kept according to guidelines of the Institute of Lab-
oratory Animal Science, Hiroshima University. The Animal Care Committee at
the Japanese Foundation for Cancer Research approved all murine studies.
Cells and Cell Culture
F-36P cells were cultured in medium described by others (Chiba et al., 1991).
Lung fibroblasts and 293 cells and their derivatives were grown in DMEM sup-
plemented with 10% FBS. LSK cells were isolated and characterized (Honda
et al., 2011;Mizuno et al., 2008), using antibodies listed in Supplemental Exper-
imental Procedures. Human CD34+ CD38 Lin, CD34+ CD38+ Lin, and Lin+
cells were isolated from cryopreserved human BM cells (TaKaRa Bio, Shiga)
(Shima et al., 2010). The stained cells were analyzed and sorted by FACSAria
II (BD Biosciences). c-Kit+ BM cells expressing Samd9L were obtained by
infecting cells with pMYs retrovirus carrying SAMD9L cDNA and IRES-GFP
followed by sorting with GFP. Cells stably expressing PDGFRb and SAMD9/
SAMD9L proteins were established by infecting cells with pMXs retrovirus
carrying the corresponding cDNA followed by selection with neomycin. Cells
expressing mouse SAMD9L or EEA1 at reduced levels were generated using
U3-deleted pMX-puro retrovirus carrying a mouse U6 promoter and a small
hairpin sequence specific for mouse SAMD9L mRNA (sh#4, target sequence:
ACAATGGAGTGATCTACTACA), or EEA1 mRNA (sh#4, CAAGAAAGCATAAA
GGAAATA; sh#8, CGGAGAAGCTGAAGAATCAGT). sh#4-resistant mouse
SAMD9L cDNA was created by replacing nucleotides in the target sequence
to CAgTGGAGcGAcCTtCTt (underline indicates replaced nucleotides),
changes that do not affect the amino acid sequence. Murine colony formation
assays were performed using MethoCult M3434 (STEMCELL Technologies,
Vancouver) according to the manufacturer’s instructions.
Quantitative Real-TimePCR, Transcriptome Analysis, Whole-Exome
Sequencing, and Determination of Copy Number
Total RNA was extracted from sorted LSK cells using RNeasy Micro Kit
(QIAGEN, Tokyo), and mRNA was purified using SuperScript VILO (Invitrogen,
Venlo). Quantitative real-time PCR was performed as previously described by
Kuribara et al. (2004) using the primer sets listed in a table in Supplemental
Experimental Procedures. Transcriptome analysis was performed using a
next-generation sequencer (GAIIx; Illumina, San Diego) according to the man-
ufacturer’s instructions. The generated sequence tags were mapped onto the
mouse genomic sequence (UCSC Genome Browser, version mm9) using the
sequence alignment program ELAND (Illumina). Whole-exome sequencing
was performed according to the method described in Supplemental Experi-
mental Procedures. Copy numbers of hSAMD9 and hSAMD9L genes were
determined using mCGH and qPCR techniques as previously described
(Asou et al., 2009).
Protein Analysis
Immunoprecipitation and immunoblot analyses and immunostaining were per-
formed according to standard procedures by Mizuno et al. (2008) and Shinjyo
et al. (2001). Cell surface and internalized PDGFRbwere isolated as previously
published procedures by others (Karlsson et al., 2006; Roberts et al., 2001) and
are described in Supplemental Experimental Procedures.
Human Samples
Written informed consent was obtained from patients with AML/MDS in accor-
dancewith theDeclarationofHelsinki forBMsampling, andanalysiswasunder-
taken with the approval of the Hiroshima University institutional review board.
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The short-read sequence archive data appearing in this paper were registered
in GenBank/DDBJ under the following accession numbers: DRA000636,
DRA000637, and DRA000638.
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